Which dialyser membrane to choose?

Nephrology Dialysis Transplantation

Volumn 19, Issue 2, 2004, Pages 293-296

  Bouré, Tony ^a   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bioincompatible; Cellulose; Dialyser; High flux; Low flux; Synthetic

Indexed keywords

CELLULOSE;

ADSORPTION; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; COMPLEMENT SYSTEM; DIALYSATE; DIALYSIS MEMBRANE; EDITORIAL; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY FAILURE; LEUKOCYTE; MOLECULE; PRACTICE GUIDELINE; PRIORITY JOURNAL; ULTRAFILTRATION;

BIOCOMPATIBLE MATERIALS; EQUIPMENT DESIGN; EQUIPMENT SAFETY; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; RENAL DIALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 1042292031     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg508     Document Type: Editorial

References (39)

1. Craddock PR, Fehr J, Dalmasso AP, Brighan KL, Jacob HS. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59: 879-888
2. Henderson LW, Miller ME, Hamilton RW, Norman ME. Hemodialysis leukopenia and polymorph random mobility - a possible correlation. J Lab Clin Med 1975; 85: 191-197
3. Hoenich NA, Woffindin C, Mathews JN, Vienken J. Biocompatibility of membranes used in the treatment of renal failure. Biomaterials 1995; 16: 587-592
4. Section II. Haemodialysis adequacy. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 16-31
5. Section III. Biocompatibility. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 32-44
6. Section VI. Causes of death in ESRD. Am J Kidney Dis 1999; 34: S87-S94
7. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476
8. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999; 55: 1945-1951
9. Schouten WE, Grooteman MP, van Houte AJ et al. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 2000; 15: 379-384
10. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 1991; 39: 320-327
11. Combe C, Pourtein M, de Precigout V et al. Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane. Am J Kidney Dis 1994; 24: 437-442
12. Dhondt AW, Vanholder RC, Waterloos MA, Glorieux GL, Ringoir SM. Leukocyte CD14 and CD45 expression during hemodialysis: polysulfone versus cuprophane. Nephron 1996; 74: 342-348
13. Pereira BJ, Snodgrass BR, Hogan PJ, King AJ. Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes. Kidney Int 1995; 47: 603-610
14. Bouman CS, van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre- and postdilution hemofiltration in four different membranes. Blood Purif 1998; 16: 261-268
15. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
16. Gejyo F, Yamada T, Odani S et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun 1985; 129: 701-706
17. Locatelli F, Mastrangelo F, Redaelli B et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50: 1293-1302
18. Raj DS, Ouwendyk M, Francoeur R, Pierratos A. Beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 2000; 15: 58-64
19. Halaas JL, Gajiwala KS, Maffei M et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-546
20. Widjaja A, Kielstein JT, Horn R et al. Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage renal disease. Nephrol Dial Transplant 2000; 15: 846-850
21. Witko-Sarsat V, Friedlander M, Nguyen KT et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532
22. Stein G, Franke S, Mahiout A et al. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001; 16: 999-1008
23. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103
24. Van Tellingen A, Grooteman MP, Bartels PC et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 2001; 59: 342-347
25. Kuchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 1996; 16: 484-488
26. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002; 61: 256-265
27. Goldberg IJ, Kaufman AM, Lavarias VA, Vanni-Reyes T, Levin NW. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 104-107
28. Robles NR, Murga L, Galvan S, Esparrago JF, Sanchez-Casado E. Hemodialysis with cuprophane or polysulfone: effects on uremic polyneuropathy. Am J Kidney Dis 1993; 21: 282-287
29. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876
30. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC. Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 2000; 15: 1029-1034
31. Bloembergen WE, Hakim RM, Stannard DC et al. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney, Dis 1999; 33: 1-10
32. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227-1237
33. Koda Y, Nishi S, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096-1101
34. Chandran PK, Liggett R, Kirkpatrick B. Patient survival on PAN/AN69 membrane hemodialysis: a ten-year analysis. J Am Soc Nephrol 1993; 4: 1199-1204
35. Churchill DN. Clinical impact of biocompatible dialysis membranes on patient morbidity and mortality: an appraisal of the evidence. Nephrol Dial Transplant 1995; 10 [Suppl 10]: 52-56
36. Hakim RM, Held PJ, Stannard DC et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50: 566-570
37. Leypoldt JK, Cheung AK, Carroll CE et al. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999; 33: 349-355
38. Port FK, Wolfe RA, Hulbert-Shearon TE et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the usrds dialysis morbidity and mortality study. Am J Kidney Dis 2001; 37: 276-286
39. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019